2nd Annual mRNA Process Development and Manufacturing Summit Europe

The 2nd mRNA Process Development and Manufacturing Summit Europe returns to reunite mRNA biopharma looking to innovate processes, speed up production and ensure the right balance is struck between quality of mRNA, efficacy of the final product, and the commercial opportunity in hand to unleash the full therapeutic value of mRNA across all disease indications.

Hear from 20+ world-class industry speakers pioneering the mRNA space in Europe, including BioNTech, MHRA, CureVac, Sanofi and more. Join us in Frankfurt this April to explore key bottlenecks from mRNA sequence design, in vitro transcription, purification, scale up and mRNA drug product development to accelerate your processes and develop safe, potent and effective mRNA drugs for infectious disease, oncology and beyond.

Join 100+ Directors, Heads and Senior Scientists of Upstream and Downstream Process Development, Analytical Development, CMC, Manufacturing and Drug Product to spur the rate of innovation, set necessary frameworks and forge meaningful partnerships to meet critical process, scale and regulatory needs that are currently preventing the mRNA community from fully realising the therapeutic and commercial opportunities offered by this disruptive class of drugs.


URLs:
Website: https://go.evvnt.com/2122146-0?pid=10018
Tickets: https://go.evvnt.com/2122146-2?pid=10018
Brochure: https://go.evvnt.com/2122146-3?pid=10018

Prices:
Drug Developer Pricing - Conference Only (on the door): EUR 2799.00,
Drug Developer Pricing - Conference + Workshop Day (on the door): EUR 3797.00,
Discounted Pricing - Conference Only (on the door): EUR 2399.00,
Discounted Pricing - Conference + Workshop Day (on the door): EUR 3197.00,
Vendor Pricing - Conference Only (on the door): EUR 3499.00,
Vendor Pricing - Conference + Workshop Day (on the door): EUR 4597.00

Speakers: Angelo Palmese, Associate Directors, Scientific Leads, Drug Product Development, GSK, Ashiqul Haque, Senior Expert Scientist - Research, Development, Chemistry Manufacturing and Control, Ziphius Vaccines NV, Bas Spaans, CMC Scientific Integrator Drug Substance Development, Janssen R AND D, Chijian Zuo, Vice President, SuZhou CureMed Biomedical Technology Co. Ltd, Cristina Bruno, Programme Manager, Consultant mRNA Technology Transfer, World Health Organization - WHO, Daniela Daubert, Senior Director Process Development, Ethris GmbH, Francis Galaway, Quality Assessor, MHRA, Franz Schnetzinger, CMC Technology Lead, CEPI, Harris Makatsoris, Professor - Sustainable Manufacturing Systems, King's College London, Marcel de Vocht, Scientific Director, Janssen R AND D, Michael Rieger, Head of mRNA Process and Chemistry, Manufacturing and Controls Data Science, Sanofi, Monica Dommel, Associate Director – Regulatory Affairs CMC, CureVac, Moritz Thran, Senior Scientist, CureVacSE, Prasun Chakraborty, Founder, Innovator and Chief Executive Officer, Genevation LTD., Rita Correro, CTO, Inofea, Shahabedin Eslami, Senior Specialist, Manufacturing Science and Technology, Providence Therapeutics, Simon Unthan, Senior Director, RNA Manufacturing Technology Development and Automation, BioNTech, Sukrut Somani, Associate Director CMC Drug Product, BioNTech, Thibaut Dempton, pDNA Development and Industrialization Leader, Sanofi, Tingting Cui, Associate Director, Process Development, AstraZeneca, Tobias von der Haar, Professor of Systems Biology, University of Kent, Zoltán Kis, Assistant Professor and Lecturer, University of Sheffield